SCHEMBL5460904

SCHEMBL5460904

COc1cccnc1NC(=O)Nc1ccc(N2CCN(C(=O)OC(C)(C)C)CC2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.55
MAPT P10636 6/20 0.55
SMN1; SMN2 Q16637 4/20 0.55
MEN1 O00255 1/20 0.55
TSHR P16473 1/20 0.55
KMT2A Q03164 1/20 0.55
P2RY1 P47900 4/20 0.49
LMNA P02545 4/20 0.48
NPC1 O15118 3/20 0.48
ALDH1A1 P00352 2/20 0.48
ESR2 Q92731 1/20 0.48
NR2F2 P24468 1/20 0.48
HTT P42858 1/20 0.48
RAB9A P51151 2/20 0.48
CCNK O75909 1/20 0.47
CCNA2 P20248 1/20 0.47
CDK2 P24941 1/20 0.47
CCND3 P30281 1/20 0.47
CDK9 P50750 1/20 0.47
CDK6 Q00534 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5452159 0.87 MAPT (0.52) NAMPTMAPTSMN1; SMN2MEN1KMT2A
SCHEMBL5459969 0.85 P2RY1 (0.58) NAMPTMAPTSMN1; SMN2MEN1TSHR
SCHEMBL5460804 0.84 MAPT (0.68) NAMPTMAPTSMN1; SMN2MEN1TSHR
SCHEMBL5462490 0.82 P2RY1 (0.60) MAPTSMN1; SMN2MEN1KMT2AP2RY1
SCHEMBL5453447 0.82 MAPT (0.56) NAMPTMAPTSMN1; SMN2MEN1TSHR
SCHEMBL5473038 0.81 MAPT (0.55) NAMPTMAPTSMN1; SMN2MEN1TSHR
SCHEMBL5460897 0.81 NAMPT (0.59) NAMPTMAPTSMN1; SMN2MEN1TSHR
SCHEMBL5466103 0.80 NAMPT (0.59) NAMPTMAPTSMN1; SMN2MEN1TSHR
SCHEMBL5470937 0.79 MAPT (0.53) NAMPTMAPTSMN1; SMN2MEN1TSHR
SCHEMBL5460938 0.78 NAMPT (0.64) NAMPTMAPTSMN1; SMN2MEN1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249620-A1 Urea Derivative SANKYO COMPANY, LIMITED (JP) 2007-10-25 US disclosed
EP-1764360-A1 UREA DERIVATIVE Sankyo Company, Limited (JP) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249620-A1 Urea Derivative UGP2, SLC14A1, DGAT1 NAMPT 324/4885MAPT 758/4885SMN1; SMN2 4424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.